Testing a new eye treatment for vision loss from macular degeneration

Plain-English translation of NCT07441642 on ClinicalTrials.gov ↗ · Source last updated October 2026 · Translation generated October 2026 · How we translate trials

Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.

What is this trial?

This trial is testing , a new medication designed to help slow vision loss in people with geographic atrophy—a condition where part of the retina (the light-sensing tissue in the back of your eye) gradually breaks down due to age-related macular degeneration. Researchers will compare three different doses of this medication against a placebo (a dummy treatment with no active ingredient) to find which dose works best and is safest.

Geographic atrophy is a serious form of age-related macular degeneration that causes progressive vision loss, and currently there are limited treatment options available. This trial is exploring whether this medication could slow that vision loss and give patients more options for preserving their sight.

Do you qualify?

You likely qualify if…

you are at least 50 years old
you have been diagnosed with geographic atrophy (a type of age-related macular degeneration) in at least one eye
your geographic atrophy lesion is a certain size—not too small and not too large—as measured by your doctor
your vision in the study eye is at a certain level (20/200 or better on an eye chart)
your geographic atrophy lesion is centered on the macula and can be fully seen in eye imaging

You likely don't qualify if…

you have choroidal neovascularization (a type of advanced wet macular degeneration) in your study eye
you have had cell or gene therapy in either eye before
you have macular atrophy from a cause other than age-related macular degeneration, such as Stargardt disease or cone-rod dystrophy
you have had eye surgery (including cataract surgery) in your study eye within the last 3 months
you have eye conditions like severe eye movement disorders, severe drooping eyelids, or significant cloudiness in your eye that would prevent clear imaging or examination

What participation looks like

You would be randomly assigned to receive one of three doses of the medication or a placebo, and neither you nor the study team would know which group you're in (that's what 'double-masked' means). You'll visit the study center multiple times so doctors can monitor how your eyes respond to the treatment using eye exams and imaging. The study involves about 272 participants across multiple centers, and your role is to take your assigned treatment as directed and return for regular check-ups to track any changes in your vision and watch for side effects.

AI-generated summary from trial data · Oct 5, 2026 · Not medical advice

Trial locations(59 sites)

United States

Salehi Retina Institute, Huntington Beach, California

Retinal Consultants Medical Group Inc, Sacramento, California

California Retina Consultants, Santa Barbara, California

Advanced Research LLC, Boynton Beach, Florida

Advanced Research LLC, Deerfield Beach, Florida